(Q36283811)

13 August 2017

1 reference

title

Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents (English)

1 reference

13 August 2017

1 reference

1

Mark O Goodarzi

1 reference

13 August 2017

Michael Bryer-Ash

2

1 reference

13 August 2017

1 November 2005

1 reference

Diabetes, Obesity and Metabolism

13 August 2017

1 reference

13 August 2017

7

1 reference

13 August 2017

654-665

1 reference

13 August 2017

6

1 reference

Lactic acidosis in biguanide-treated diabetics: a review of 330 cases

13 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Farewell to phenformin for treating diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Antidiabetic Drugs After the University Group Diabetes Program (UGDP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Metformin increases insulin sensitivity and basal glucose clearance in Type 2 (non-insulin dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Improved endothelial function with metformin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Effect of Metformin and Sulfonylurea on C-Reactive Protein Level in Well-Controlled Type 2 Diabetics with Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Metformin in management of pregnant insulin-independent diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Oral hypoglycaemic agents in 118 diabetic pregnancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Effects of metformin on early pregnancy loss in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

The importance of insulin resistance in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Cholestatic jaundice associated with the use of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Reduction of metformin renal tubular secretion by cimetidine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Disposition of metformin (N,N-dimethylbiguanide) in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Combining sulfonylureas and other oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

Comparison of pioglitazone and metformin efficacy using homeostasis model assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00448.X

10.1111/J.1463-1326.2004.00448.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16219009